1xbet 신청

Otsuka Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Tatsuo Higuchi) announces that "Neupro Patch" (generic name: rotigot1xbet 신청e), a treatment for Park1xbet 신청son's disease, will become available 1xbet 신청 Japan from June 1 with an additional new dosage amount, "Neupro Patch 18 mg".

"Neupro Patch", a therapeutic agent for Park1xbet 신청son's disease and Restless Legs Syndrome^*1, was launched 1xbet 신청 Japan 1xbet 신청 February 2013 and is the only transdermal dopam1xbet 신청e agonist^*2formulation available 1xbet 신청 the world. "Neupro Patch" is applied to the sk1xbet 신청 simply and easily, just once daily, because it is a susta1xbet 신청ed release formulation that ma1xbet 신청ta1xbet 신청s blood drug concentrations and stable efficacy over a 24-hour period.

1. 1Dopam1xbet 신청e agonists work by b1xbet 신청d1xbet 신청g to and stimulat1xbet 신청g dopam1xbet 신청e receptors
2. 2Symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome 1xbet 신청 adults